Prior studies that focused on HER2 amplified breast cancers showed that FAK inhibition in combination with trastuzumab (a HER2 specific antagonist) resulted in suppression of cellular growth and increased response to HER2 inhibition (Lazaro et al., 2013). Here, ERBB2 is linked to breast carcinoma.